Page 50 - BPOM Terbitkan EUA Vaksin Indovac dan Vaksin AWcorna

Judul : AWCorna Becomes First Domestically-Produced mRNA COVID-19
Vaccine: BPOM
Nama Media : medcom.id
Tanggal : 9/30/2022
Halaman/URL : https://www.medcom.id/english/national/GbmBM0Lk-awcorna-
becomes-first-domestically-produced-mrna-covid-19-vaccine-bpom
Tipe Media : Media Online

AWcorna becomes the first mRNA
COVID-19 vaccine trademark to be
developed and produced in Indonesia,
Food and Drug Supervisory Agency
(BPOM) Head Penny K. Lukito stated.

The Emergency Use Authorization
(EUA) approval for this vaccine offers
another alternative option in the
COVID-19 vaccination program for
adults, she noted during the press
conference on EUA provision for
domestic vaccine here, Friday.

AWcorna is registered by a private
pharmaceutical company PT Etana
Biotechnologies Indonesia (PT Etana) and developed through a transfer of technology and
research along with private company Abogen-Yuxi Walvax based in China.

"While it is categorized as an mRNA platform vaccine, this vaccine can be stored at
temperatures of two to eight degrees Celsius," Lukito noted.

Development of the mRNA platform is undertaken in the company's production facility
located in Pulogadung, East Jakarta.

mRNA or messenger RNA vaccine is the latest type of vaccination that differs from other
types of vaccines.

If conventional vaccine contains a weakened or deactivated virus or bacteria, mRNA vaccine
is produced with the latest technology as a result of biotechnology development.